394 related articles for article (PubMed ID: 24190997)
1. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Batchelor TT; Gerstner ER; Emblem KE; Duda DG; Kalpathy-Cramer J; Snuderl M; Ancukiewicz M; Polaskova P; Pinho MC; Jennings D; Plotkin SR; Chi AS; Eichler AF; Dietrich J; Hochberg FH; Lu-Emerson C; Iafrate AJ; Ivy SP; Rosen BR; Loeffler JS; Wen PY; Sorensen AG; Jain RK
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19059-64. PubMed ID: 24190997
[TBL] [Abstract][Full Text] [Related]
2. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Nabors LB; Mikkelsen T; Hegi ME; Ye X; Batchelor T; Lesser G; Peereboom D; Rosenfeld MR; Olsen J; Brem S; Fisher JD; Grossman SA;
Cancer; 2012 Nov; 118(22):5601-7. PubMed ID: 22517399
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
4. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
7. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Sorensen AG; Emblem KE; Polaskova P; Jennings D; Kim H; Ancukiewicz M; Wang M; Wen PY; Ivy P; Batchelor TT; Jain RK
Cancer Res; 2012 Jan; 72(2):402-7. PubMed ID: 22127927
[TBL] [Abstract][Full Text] [Related]
8. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Pinho MC; Polaskova P; Kalpathy-Cramer J; Jennings D; Emblem KE; Jain RK; Rosen BR; Wen PY; Sorensen AG; Batchelor TT; Gerstner ER
Oncologist; 2014 Jan; 19(1):75-81. PubMed ID: 24309981
[TBL] [Abstract][Full Text] [Related]
10. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
[TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
12. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
13. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
Momeny M; Shamsaiegahkani S; Kashani B; Hamzehlou S; Esmaeili F; Yousefi H; Irani S; Mousavi SA; Ghaffari SH
Life Sci; 2021 Dec; 287():120100. PubMed ID: 34715143
[TBL] [Abstract][Full Text] [Related]
14. [Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Matsko MV; Luchin EI; Ievleva AG; Bakholdin DV; Abysheva SN; Zavgorodniaia EV; Potapova ON; Imianitov EN; Ulitin AIu; Matsko DE
Vopr Onkol; 2011; 57(2):245-9. PubMed ID: 21809674
[TBL] [Abstract][Full Text] [Related]
15. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Gerstner ER; Eichler AF; Plotkin SR; Drappatz J; Doyle CL; Xu L; Duda DG; Wen PY; Jain RK; Batchelor TT
J Neurooncol; 2011 Jun; 103(2):325-32. PubMed ID: 20821342
[TBL] [Abstract][Full Text] [Related]
18. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Sorensen AG; Batchelor TT; Zhang WT; Chen PJ; Yeo P; Wang M; Jennings D; Wen PY; Lahdenranta J; Ancukiewicz M; di Tomaso E; Duda DG; Jain RK
Cancer Res; 2009 Jul; 69(13):5296-300. PubMed ID: 19549889
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]